In this video, Dawn Bitz, CEO of Adherium, discusses how their innovative respiratory remote patient monitoring (RPM) platform is revolutionising healthcare for patients with respiratory conditions. Adherium has developed smart-jacket sensors that enhance medication adherence, significantly improving patient outcomes and reducing hospitalisation costs. With impressive data from their collaboration with Intermountain Health, including a 235% improvement in adherence, Dawn shares key insights on how their technology is designed to benefit both patients and healthcare providers.

Join us as we break down the technology, the business strategy, and the future prospects of Adherium, targeting an ambitious growth in RPM patients by 2026. Whether you're an investor or just curious about healthcare innovations, this is a must-watch.

**Timestamps:**

00:00 Introduction to Dawn Bitz

00:12 Overview of Adherium's role in healthcare

00:42 The importance of medication adherence

01:30 The smart-jacket technology explained

02:00 How it works for patient data collection

02:30 Cost reductions through adherence

03:10 Key insights from the partnership with Intermountain Health

03:50 Future growth plans and targets for 2026

04:30 Closing thoughts and what’s next for Adherium

Stay tuned for more updates on how Adherium is making a real change in patient care. Don't forget to like, share, and subscribe for the latest in ASX small-cap news!

⚠️ IMPORTANT DISCLAIMER: This content is for educational and entertainment purposes only and should not be considered financial advice. All investments carry risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consider seeking advice from a qualified financial advisor before making investment decisions. The creator may hold positions in securities discussed.

📌 Articles:

https://smallcaps.com.au/australian-market-follows-wall-street-down-market-wrap

https://smallcaps.com.au/adherium-partners-astrazeneca-hailie-smartinhaler-clinical-trial

https://smallcaps.com.au/adherium-hailie-smartinhaler-fda-approval-astrazeneca-devices

https://smallcaps.com.au/adherium-us-health-group-remote-medical-management-high-risk-respiratory-patients

https://smallcaps.com.au/adherium-receives-fda-grant-market-smartinhaler-us

🔎 More on Adherium:

https://smallcaps.com.au/stocks/asx-adr/

⸻

Small Caps is Australia’s #1 site for market news & information on ASX-listed small cap companies.

🌐 WEBSITE

https://smallcaps.com.au/

🎧 PODCAST

https://smallcaps.com.au/podcast/

📱 SOCIAL MEDIA

Facebook: https://www.facebook.com/SmallCapsASX

Twitter: https://twitter.com/SmallCapsASX

LinkedIn: https://www.linkedin.com/company/small-caps/

📬 NEWSLETTER

https://smallcaps.com.au/subscribe/